Diamedica Therapeutics Inc. · NASDAQ:DMAC
Diamedica Therapeutics — Corporate Update (June 2021)
15 slides from Diamedica Therapeutics's corporate update, Jun 29, 2021
Slide 1: DM199 REDUX Phase 2 CKD Interim Results
DM199 REDUX Phase 2 CKD Interim Results June 29 2021
Slide 2: Cautionary Note Regarding Forward Looking Statements
Cautionary Note Regarding Forward Looking Statements 1995 and the words ‘estimate’ "believe! “anticipate “intend “expect “plan, ‘continu,“look forward, “wil "may! “potentially” or ‘should the the sopulation. Such statement By their nature, forward-looking chievernents, oF RED M199; our plans to dewi
Slide 3: REDUX Interim Analysis
REDUX Interim Analysis Encouraging data to support further study of DM199 in kidney disease and stroke DM199 has been safe and well tolerated in the REDUX study * No safety or tolerability concerns after 3 months of dosing with 62 patients and over 1,500 injections * Data consistent with data from t
Slide 4: Phase 2 REDUX Study - Safety and Signal Seeking for DM199 in CKD
Phase 2 REDUX Study - Safety and Signal Seeking for DM199 in CKD Key Objectives . Safety and tolerability o Repeat injections over three months © Benchmark to approved porcine KLK1 from Asia © Signals of clinically relevant activity Measured by UACR, eGFR and BP Analysis of Clinical Data, PK and Bio
Slide 5: Kidney Disease Populations Studied with DM199 With High Unmet Medical Needs
Kidney Disease (CKD) Popula ions Studied with DM199 ith High Unmet Medical Needs IgA Nephropathy (IgAN) * Serious and progressive autoimmune disease of Kicneys * Up to 50% at risk of developing ESRD within 10-20 yes = Orphan disease indication in US (~140K) and Europe (200K, ~ = No approved treatmen
Slide 6: CKD Patients - Kidney Function Worsens Over Time
CKD Patients - Kidney Function Worsens Over Time Average Annual eGFR Decline Standard of care only reduces slope of decline ° + Slowing eGFR decline an important endpoint in kidney disease L - Reducing UACR is a surrogate i : 36 endpoint for predicting kidney Ble oF disease progression and allows fo
Slide 7: DM199 REDUX Phase 2 CKD Study Design
DM199 REDUX Phase 2 CKD Study Design Study Includes 3 Distinct Causes of CKD SSS fe ea ee (WSs pe Re Tar mana ‘Sample Size African metas, hypertensive with CKD = “2 @ Cohorts) IgA Nephro n=-30 _n=28 .GFR 30-90 mL/min Albuminuria: 150 ~ 5,000 95 days of treatment SC dosing, 2x week D Topline data Day
Slide 8: Analysis Population: Patient Disposition and Baseline Demographics
Analysi: ion: Patient Disposition and Baseline Di Baseline Demographics - Analysis Population aa a A Ge = aaa ESTEE aT African Iga 8 DiaMedica
Slide 9: Safety and Tolerability of DM199 - Consistent with Earlier Studies
lerability of DM199 - Consi: with Earlier Studies Excellent Safety and 62 patients completed study and over 1,500 injections - June 2021 + No discontinuations due to drug-related adverse events + No drug-related SAEs © No drug-related i or fluid cd + AEs were been generally mild-to-moderate lated AE
Slide 10: Hypertensive African Americans with CKD - Positive Signals
Hypertensive African Americans with CKD — Positive Signals in Reducing UACR, Increasing eGFR and Reducing BP ‘Albuminuria (UACR) Busine >150 —_Basline > 500 sth aah ar ne eo) 3 2 + Reductions most significant in moderate ‘to severe patients (UACR>500} Reductions more significant atthe lower dose lev
Slide 11: IgA Nephropathy — Interim Analysis
IgA Nephropathy — Interim Analysis Positive Signals in Decreasing UACR and Stabilizing eGFR Albuminuria (UACR) eGFR Sesclne 150mg sine 00 9/9 nn ‘n8, sei 1.73 Blood Pressure Systolic Diastolic ‘nis, Stable/did not decrease BP in compared to baseline in moderate to severe patients (UACR>500) + Not su
Slide 12: Diabetic Kidney Disease — Interim Analysis
Diabetic Kidney Disease — Interim Analysis Positive Signals - Reducing Blood Pressure No Change in UACR and Stabilizing eGFR Blood Pressure Albuminuria (UACR) GFR afta ee fh come “ eli BP in a i ‘these hypotensive patients . + Reductions statistically significant (10-1) in lower dose cohort (n= 18)
Slide 13: Interim Results Affirm Biological Activity and Safety of DM199
Interim Results Affirm Biological Activity and Safety of DM199 Consistent with MOA and Approved KLK1 Product in Asia ¥ Clinically relevant signals in patients with CKD » UACR > eGFR > Hypertension v Safe and Well Tolerated — No SAE or AE concerns related to DM199 (1,500+ injections) ¥ Data consisten
Slide 14: Priorities and Next Steps for DiaMedica
Priorities and Next Steps for DiaMedica Continue Phase 2 CKD Study and Initiate Pivotal Study for Acute Ischemic Stroke (AIS) Complete Phase 2 Enrollment for IgAN and Hypertensive African Americans with CKD Analyze full CKD data set before initiating additional studies in CKD * Larger sample size by
Slide 15: Thank you!
8"Z DiaMedi MS THERAPEU t NASDAQ: DMAC oy ca cs Thank you!
DiaMedica Therapeutics — Corporate Update (June 2021) on 6ix